XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Deferred Revenue $ 179,851 $ 175,646
U.S./RoW and China [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 1,165,393  
Deferred Revenue 179,851  
Total Consideration 1,345,244  
U.S./RoW and China [Member] | License Revenue [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 344,493  
Deferred Revenue 0  
Total Consideration 344,493  
U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 625,111  
Deferred Revenue 0  
Total Consideration 625,111  
U.S./RoW and China [Member] | China performance obligation [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 195,789  
Deferred Revenue 179,851  
Total Consideration $ 375,640